Gene responsible for mesenchymal stem cells’ ‘stem-ness’ identified – Science Daily
Christian Post |
Gene responsible for mesenchymal stem cells‘ ‘stem-ness’ identified
Science Daily Mesenchymal stem cells (MSCs) are popular tools for these therapies because they can differentiate into a variety of mature cell types such as bone, fat and cartilage. They also support hematopoiesis — the formation of blood cells — and secrete … Scientists Develop New Method to Create Stem Cells Without Killing Human EmbryosChristian Post |
Endpoints News |
Spark licenses blindness gene therapy rights outside US to Novartis
Reuters In a statement, Spark said the deal leverages Novartis’ “large, existing commercial and medical infrastructure in ophthalmology, as well as its commitment to commercializing genetic-based medicines.” Novartis, which sells opthalmology drugs including … Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M dealEndpoints News Novartis strikes $170m deal for ex-US rights to gene therapy for blindnessFinancial Times Novartis Pays Spark $105M Up Front for Gene Therapy Rights Outside USXconomy Philly.com (blog) –Labiotech.eu (blog) –pharmaphorum all 25 news articles » |
The San Diego Union-Tribune |
Sorrento Therapeutics expands cancer treatment manufacturing on East Coast
The San Diego Union-Tribune Located in Providence, Rhode Island at Roger Williams Medical Center, the new center, together with Sorrento’s San Diego CAR T facility, allows the company to make treatments for about 300 patients a year. The company has one CAR T product in clinical … |
Endpoints News |
Novartis steps in to grab ex-US rights to pioneering gene therapy Luxturna with $170M deal
Endpoints News Just days ahead of Vas Narasimhan’s jump into the CEO’s spot, Novartis has swooped in with a $170 million deal to grab ex-US rights on Spark Therapeutics’ Luxturna, the first true gene therapy to get a US approval. The pharma giant is paying $105 … Novartis strikes $170m deal for ex-US rights to gene therapy for blindnessFinancial Times Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for …GlobeNewswire (press release) Spark licenses blindness gene therapy rights outside US to NovartisReuters Nasdaq all 5 news articles » |
|
Could Stem Cells Eventually End the Transplant Organ Shortage?
HowStuffWorks If a patient’s own stem cells could be manipulated to grow a personalized replacement for an ailing heart, liver, kidneys or another organ, that would help solve the supply/match problem. Additionally, a transplant organ wouldn’t face the risk of … |